Sandra Kurtin, NP
Nurse Practitioner · Tucson, AZNPI 1700985009
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (56.4%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. It is spread thinly across 27 manufacturers, the largest accounting for just 11.9%. Reporting peaked in 2021 at $69,629 and has fallen 66.3% since, to $23,434 in 2025. Among nurse practitioner clinicians in AZ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 272 payments — averaging $738.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Incyte Corporation$24K
- AstraZeneca$21K
- Agios Pharmaceuticals, Inc.$18K
- Takeda Pharmaceuticals U.S.A., Inc.$18K
- Jazz Pharmaceuticals Inc.$18K
- AbbVie$17K
- plus $84K from 21 others
What the payments were for
- Consulting fees$56,63128%
- Speaking & faculty fees$113,34656%
- Travel & lodging$24,64012%
- Food & beverage$5,9603%
- Education$2980%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Incyte Corporation | 39 | $23,997 |
| AstraZeneca | 30 | $21,191 |
| Agios Pharmaceuticals, Inc. | 27 | $18,280 |
| Takeda Pharmaceuticals U.S.A., Inc. | 17 | $17,865 |
| Jazz Pharmaceuticals Inc. | 6 | $17,828 |
| AbbVie | 35 | $17,419 |
| GSK | 19 | $15,452 |
| Sanofi | 14 | $11,284 |
| Bristol Myers Squibb | 13 | $10,293 |
| Amgen | 11 | $8,747 |
| Blueprint Medicines Corporation | 10 | $7,073 |
| E.r. Squibb & Sons, L.L.C. | 6 | $5,692 |
| Pharmacyclics LLC, An Abbvie Company | 9 | $5,410 |
| Taiho Oncology, Inc. | 7 | $3,647 |
| Pfizer | 6 | $2,880 |
| Epizyme, Inc. | 5 | $2,850 |
| Johnson & Johnson | 4 | $1,914 |
| Genentech USA, Inc. | 4 | $1,858 |
| Genentech, Inc. | 1 | $1,850 |
| Daiichi Sankyo Inc. | 2 | $1,828 |
| Astrazeneca UK Limited | 1 | $1,160 |
| ADC Therapeutics America, Inc. | 1 | $900 |
| CTI Biopharma Corp. | 1 | $700 |
| Seagen Inc. | 1 | $425 |
| TG Therapeutics, Inc. | 1 | $185 |
| Astellas Pharma US Inc | 1 | $98 |
| Ipsen Biopharmaceuticals, Inc | 1 | $49 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$200,874 in reported general payments places this provider in the 95th percentile of 1,719 nurse practitioner providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JakafiRuxolitinib Phosphate | 80 | $1,331,370 |
| RevlimidLenalidomide | 57 | $920,153 |
| PomalystPomalidomide | 13 | $323,319 |
| BesremiRopeginterferon Alfa-2b-Njft | 16 | $269,276 |
| ImbruvicaIbrutinib | 16 | $254,221 |
| TasignaNilotinib Hcl | 22 | $253,291 |
| Lenalidomide | 14 | $191,311 |
| PromactaEltrombopag Olamine | 16 | $190,662 |
| SprycelDasatinib | 27 | $177,932 |
| VenclextaVenetoclax | 13 | $106,585 |
| Imatinib Mesylate | 40 | $86,979 |
| EliquisApixaban | 52 | $66,770 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 16 | $25,262 |
| XareltoRivaroxaban | 16 | $12,092 |
| Hydroxyurea | 121 | $3,436 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Incyte CorporationJakafi | $23,997 | $1,331,37080 claims |
| Bristol Myers SquibbRevlimid | $10,293 | $920,15357 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst, Sprycel | $5,692 | $501,25140 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $5,410 | $254,22116 claims |
| AbbVieVenclexta | $17,419 | $106,58513 claims |
| PfizerEliquis | $2,880 | $66,77052 claims |
| Johnson & JohnsonXarelto | $1,914 | $12,09216 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,719 nurse practitioner providers in Arizona.
Other nurse practitioner in Tucson
- Joseph DeboeTucson$22K
- Hillary CampbellTucson$16K
- Laura ZimmermanTucson$16K
- Svetlana BurtmanTucson$12K
- Gretchen CrawfordTucson$11K
- Kristina TrafeletTucson$10K
- Ann MooreGlendale$208K
- Kristen HerzogScottsdale$162K
- Krista ArredondoChandler$133K
- Shannon MorgensternOro Valley$71K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.